β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy

Seminars in Cancer Biology

Volumn 23, Issue 6 PB, 2013, Pages 533-542

  Tang, Jing ^a   Li, Zhijie ^b   Lu, Lan ^b   Cho, Chi Hin ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Angiogenesis; Nicotine; Stress hormones; Tumour progression; Adrenergic system; Adrenoceptors; Blockers

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 AMINOBUTYRIC ACID; ANTINEOPLASTIC AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CELECOXIB; CIGARETTE SMOKE; CISPLATIN; DOPAMINE; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METOPROLOL; NICOTINE; PROPRANOLOL; STRESS HORMONE; VASCULOTROPIN;

ADRENERGIC SYSTEM; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CELL INVASION; CELL PROLIFERATION; DRUG ABSORPTION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPERTENSION; MELANOMA; METASTASIS; NONHUMAN; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; AC; ACTIVATOR PROTEIN 1; ADENYLYL CYCLASE; ANGIOGENESIS; AP1; BAD; BCL2-ASSOCIATED DEATH PROTEIN; CAMP; CAMP RESPONSE ELEMENT BINDING PROTEIN; CREB; CYCLIC AMP; DOPAMINE RECEPTOR; DR; EC; ENDOTHELIAL CELLS; EPAC; EXCHANGE PROTEIN ACTIVATED BY ADENYLYL CYCLASE; FAK; FOCAL ADHESION KINASE; GABA; GROWTH-REGULATED ONCOGENE ALPHA; GROΑ; HIF-1Α; HISTIDINE-RICH GLYCOPROTEIN; HRG; HYPOXIA-INDUCIBLE FACTOR-1; IL-6; INTERLEUKIN-6; MAPK; MATRIX METALLOPROTEINASE; MITOGEN-ACTIVATED PROTEIN KINASE; MMP; NACHR; NF-ΚB; NICOTINE; NICOTINIC ACETYLCHOLINE RECEPTORS; NNK; NUCLEAR FACTOR-ΚB; P70S6 KINASE; P70S6K; PDGF; PERIVASCULAR CELL; PHOSPHOINOSITIDE 3-KINASE; PI3K; PKA; PLACENTA-DERIVED GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR; PLGF; PROTEIN KINASE A; PVC; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION-3; STAT3; STRESS HORMONES; TAM; TGF-Β; TRANSFORMING GROWTH FACTOR Β; TUMOR ASSOCIATED MACROPHAGES; TUMOUR PROGRESSION; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF; Β-ADRENERGIC SYSTEM; Β-ADRENOCEPTORS; Β-BLOCKERS; Γ-AMINOBUTYRIC ACID;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; APOPTOSIS; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 84887609771     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.08.009     Document Type: Review

References (117)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
3. Li Z.J., Cho C.H. Neurotransmitters, more than meets the eye - neurotransmitters and their perspectives in cancer development and therapy. Eur J Pharmacol 2011, 667:17-22.
4. Entschladen F., Palm D., Lang K., Lt Drell T., Zaenker K.S. Neoneurogenesis: tumors may initiate their own innervation by the release of neurotrophic factors in analogy to lymphangiogenesis and neoangiogenesis. Med Hypotheses 2006, 67:33-35.
5. Schuller H.M. Neurotransmission and cancer: implications for prevention and therapy. Anticancer Drugs 2008, 19:655-671.
6. Voss M.J., Entschladen F. Tumor interactions with soluble factors and the nervous system. Cell Commun Signal 2010, 8:21.
7. Palm D., Entschladen F. Neoneurogenesis and the neuro-neoplastic synapse. Prog Exp Tumor Res 2007, 39:91-98.
8. Li S., Sun Y., Gao D. Role of the nervous system in cancer metastasis. Oncol Lett 2013, 5:1101-1111.
9. Tilan J., Kitlinska J. Sympathetic neurotransmitters and tumor angiogenesis-link between stress and cancer progression. J Oncol 2010, 2010:539706.
10. Thaker P.H., Sood A.K. Neuroendocrine influences on cancer biology. Semin Cancer Biol 2008, 18:164-170.
11. Wong H.P., Yu L., Lam E.K., Tai E.K., Wu W.K., Cho C.H. Nicotine promotes cell proliferation via alpha7-nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. Toxicol Appl Pharmacol 2007, 221:261-267.
12. Wong H.P., Yu L., Lam E.K., Tai E.K., Wu W.K., Cho C.H. Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol Sci. 2007, 97:279-287.
13. Al-Wadei H.A., Schuller H.M. Nicotinic receptor-associated modulation of stimulatory and inhibitory neurotransmitters in NNK-induced adenocarcinoma of the lungs and pancreas. J Pathol 2009, 218:437-445.
14. Schuller H.M., Al-Wadei H.A. Neurotransmitter receptors as central regulators of pancreatic cancer. Future Oncol 2010, 6:221-228.
15. Antoni M.H., Lutgendorf S.K., Cole S.W., Dhabhar F.S., Sephton S.E., McDonald P.G., et al. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 2006, 6:240-248.
16. Costanzo E.S., Sood A.K., Lutgendorf S.K. Biobehavioral influences on cancer progression. Immunol Allergy Clin North Am 2011, 31:109-132.
17. Lutgendorf S.K., Sood A.K., Antoni M.H. Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol 2010, 28:4094-4099.
18. Lang K., Bastian P. Neurotransmitter effects on tumor cells and leukocytes. Prog Exp Tumor Res 2007, 39:99-121.
19. Shi M., Liu D., Yang Z., Guo N. Central and peripheral nervous systems: master controllers in cancer metastasis. Cancer Metastasis Rev 2013, [E-pub ahead of print].
20. Engler H., Bailey M.T., Engler A., Sheridan J.F. Effects of repeated social stress on leukocyte distribution in bone marrow, peripheral blood and spleen. J Neuroimmunol 2004, 148:106-115.
21. Lutgendorf S.K., DeGeest K., Dahmoush L., Farley D., Penedo F., Bender D., et al. Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun 2011, 25:250-255.
22. Schuller H.M., Al-Wadei H.A., Ullah M.F., Plummer H.K. Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention. Carcinogenesis 2012, 33:191-196.
23. Hermes G.L., Delgado B., Tretiakova M., Cavigelli S.A., Krausz T., Conzen S.D., et al. Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc Natl Acad Sci USA 2009, 106:22393-22398.
24. Thaker P.H., Han L.Y., Kamat A.A., Arevalo J.M., Takahashi R., Lu C., et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006, 12:939-944.
25. Lee J.W., Shahzad M.M., Lin Y.G., Armaiz-Pena G., Mangala L.S., Han H.D., et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 2009, 15:2695-2702.
26. Wong H.P., Ho J.W., Koo M.W., Yu L., Wu W.K., Lam E.K., et al. Effects of adrenaline in human colon adenocarcinoma HT-29 cells. Life Sci 2011, 88:1108-1112.
27. Liu X., Wu W.K., Yu L., Sung J.J., Srivastava G., Zhang S.T., et al. Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via beta-adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway. J Cell Biochem 2008, 105:53-60.
28. Al-Wadei H.A., Ullah M.F., Al-Wadei M.H. Intercepting neoplastic progression in lung malignancies via the beta adrenergic (beta-AR) pathway: implications for anti-cancer drug targets. Pharmacol Res 2012, 66:33-40.
29. Al-Wadei H.A., Plummer H.K., Ullah M.F., Unger B., Brody J.R., Schuller H.M. Social stress promotes and gamma-aminobutyric acid inhibits tumor growth in mouse models of non-small cell lung cancer. Cancer Prev Res (Phila) 2012, 5:189-196.
30. Sastry K.S., Karpova Y., Prokopovich S., Smith A.J., Essau B., Gersappe A., et al. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem. 2007, 282:14094-14100.
31. Yang E.V., Sood A.K., Chen M., Li Y., Eubank T.D., Marsh C.B., et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006, 66:10357-10364.
32. Moretti S., Massi D., Farini V., Baroni G., Parri M., Innocenti S., et al. beta-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab Invest 2013, 93:279-290.
33. Lamkin D.M., Sloan E.K., Patel A.J., Chiang B.S., Pimentel M.A., Ma J.C., et al. Chronic stress enhances progression of acute lymphoblastic leukemia via beta-adrenergic signaling. Brain Behav Immun 2012, 26:635-641.
34. Inbar S., Neeman E., Avraham R., Benish M., Rosenne E., Ben-Eliyahu S. Do stress responses promote leukemia progression? An animal study suggesting a role for epinephrine and prostaglandin-E2 through reduced NK activity. PLoS ONE 2011, 6:e19246.
35. Stiles J.M., Amaya C., Rains S., Diaz D., Pham R., Battiste J., et al. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PLoS ONE 2013, 8:e60021.
36. Sood A.K., Armaiz-Pena G.N., Halder J., Nick A.M., Stone R.L., Hu W., et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 2010, 120:1515-1523.
37. Hassan S., Karpova Y., Baiz D., Yancey D., Pullikuth A., Flores A., et al. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest 2013, 123:874-886.
38. Wu W.K., Wong H.P., Luo S.W., Chan K., Huang F.Y., Hui M.K., et al. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone from cigarette smoke stimulates colon cancer growth via beta-adrenoceptors. Cancer Res 2005, 65:5272-5277.
39. Perez Pinero C., Bruzzone A., Sarappa M.G., Castillo L.F., Luthy I.A. Involvement of alpha2- and beta2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol 2012, 166:721-736.
40. Carie A.E., Sebti S.M. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene 2007, 26:3777-3788.
41. Luthy I.A., Bruzzone A., Pinero C.P., Castillo L.F., Chiesa I.J., Vazquez S.M., et al. Adrenoceptors: non conventional target for breast cancer. Curr Med Chem 2009, 16:1850-1862.
42. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011, 17:1359-1370.
43. Sarkar C., Chakroborty D., Basu S. Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines. J Neuroimmune Pharmacol 2013, 8:7-14.
44. Sakurai T., Kudo M. Signaling pathways governing tumor angiogenesis. Oncology 2011, 81(Suppl. 1):24-29.
45. Vilardi B.M., Bravo-Calderon D.M., Bernabe D.G., Oliveira S.H., Oliveira D.T.V.E.G.F-C. expression in oral cancer by neurotransmitter-induced activation of beta-adrenergic receptors. Tumour Biol 2013, 34:139-143.
46. Yang E.V., Kim S.J., Donovan E.L., Chen M., Gross A.C., Webster Marketon J.I., et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009, 23:267-275.
47. Madden K.S., Szpunar M.J., Brown E.B. beta-Adrenergic receptors (beta-AR) regulate VEGF and IL-6 production by divergent pathways in high beta-AR-expressing breast cancer cell lines. Breast Cancer Res Treat. 2011, 130:747-758.
48. Lutgendorf S.K., Lamkin D.M., Jennings N.B., Arevalo J.M., Penedo F., DeGeest K., et al. Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res 2008, 14:6839-6846.
49. Rogers T.L., Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med 2011, 9:177.
50. Coffelt S.B., Hughes R., Lewis C.E. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 2009, 1796:11-18.
51. Park S.Y., Kang J.H., Jeong K.J., Lee J., Han J.W., Choi W.S., et al. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism. Int J Cancer 2011, 128:2306-2316.
52. Spano D., Heck C., De Antonellis P., Christofori G., Zollo M. Molecular networks that regulate cancer metastasis. Semin Cancer Biol 2012, 22:234-249.
53. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
54. Benish M., Bartal I., Goldfarb Y., Levi B., Avraham R., Raz A., et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 2008, 15:2042-2052.
55. Goldfarb Y., Sorski L., Benish M., Levi B., Melamed R., Ben-Eliyahu S. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg 2011, 253:798-810.
56. Wu W., Murata J., Hayashi K., Yamaura T., Mitani N., Saiki I. Social isolation stress impairs the resistance of mice to experimental liver metastasis of murine colon 26-L5 carcinoma cells. Biol Pharm Bull 2001, 24:772-776.
57. Sood A.K., Bhatty R., Kamat A.A., Landen C.N., Han L., Thaker P.H., et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006, 12:369-375.
58. Guo K., Ma Q., Wang L., Hu H., Li J., Zhang D., et al. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 2009, 22:825-830.
59. Lang K., Lt Drell T., Lindecke A., Niggemann B., Kaltschmidt C., Zaenker K.S., et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004, 112:231-238.
60. Zhang D., Ma Q.Y., Hu H.T. Zhang M. beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkappaB and AP-1. Cancer Biol Ther 2010, 10:19-29.
61. Landen C.N., Lin Y.G., Armaiz Pena G.N., Das P.D., Arevalo J.M., Kamat A.A., et al. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 2007, 67:10389-10396.
62. Strell C., Niggemann B., Voss M.J., Powe D.G., Zanker K.S., Entschladen F. Norepinephrine promotes the beta1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROalpha release. Mol Cancer Res 2012, 10:197-207.
63. Sloan E.K., Priceman S.J., Cox B.F., Yu S., Pimentel M.A., Tangkanangnukul V., et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010, 70:7042-7052.
64. Palm D., Lang K., Niggemann B., Lt Drell T., Masur K., Zaenker K.S., et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006, 118:2744-2749.
65. Schuller H.M. Neurotransmitter receptor-mediated signaling pathways as modulators of carcinogenesis. Prog Exp Tumor Res 2007, 39:45-63.
66. Dasgupta P., Rizwani W., Pillai S., Kinkade R., Kovacs M., Rastogi S., et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 2009, 124:36-45.
67. Chen C.S., Lee C.H., Hsieh C.D., Ho C.T., Pan M.H., Huang C.S., et al. Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins. Breast Cancer Res Treat 2011, 125:73-87.
68. Chen R.J., Ho Y.S., Guo H.R., Wang Y.J. Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci 2008, 104:283-293.
69. Weddle D.L., Tithoff P., Williams M., Schuller H.M. Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 2001, 22:473-479.
70. Schuller H.M., Tithof P.K., Williams M., Plummer H. The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 1999, 59:4510-4515.
71. Jull B.A., Plummer H.K., Schuller H.M. Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J Cancer Res Clin Oncol 2001, 127:707-717.
72. Al-Wadei M.H., Al-Wadei H.A., Schuller H.M. Pancreatic cancer cells and normal pancreatic duct epithelial cells express an autocrine catecholamine loop that is activated by nicotinic acetylcholine receptors alpha3, alpha5, and alpha7. Mol Cancer Res 2012, 10:239-249.
73. Ye Y.N., Liu E.S., Shin V.Y., Wu W.K., Cho C.H. The modulating role of nuclear factor-kappaB in the action of alpha7-nicotinic acetylcholine receptor and cross-talk between 5-lipoxygenase and cyclooxygenase-2 in colon cancer growth induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone. J Pharmacol Exp Ther 2004, 311:123-130.
74. Liu E.S., Shin V.Y., Ye Y.N., Luo J.C., Wu W.K., Cho C.H. Cyclooxygenase-2 in cancer cells and macrophages induces colon cancer cell growth by cigarette smoke extract. Eur J Pharmacol 2005, 518:47-55.
75. Ye Y.N., Wu W.K., Shin V.Y., Bruce I.C., Wong B.C., Cho C.H. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005, 26:827-834.
76. Shin V.Y., Wu W.K., Ye Y.N., So W.H., Koo M.W., Liu E.S., et al. Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2. Carcinogenesis 2004, 25:2487-2495.
77. Wong H.P., Li Z.J., Shin V.Y., Tai E.K., Wu W.K., Yu L., et al. Effects of cigarette smoking and restraint stress on human colon tumor growth in mice. Digestion 2009, 80:209-214.
78. Shin V.Y., Jin H.C., Ng E.K., Yu J., Leung W.K., Cho C.H., et al. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: Involvement of nicotinic acetylcholine receptor (nAChR) and beta-adrenergic receptor signaling pathways. Toxicol Appl Pharmacol 2008, 233:254-261.
79. Li P., Wu W.K., Wong H.P., Zhang S.T., Yu L., Cho C.H. Chloroform extract of cigarette smoke induces proliferation of human esophageal squamous-cell carcinoma cells: modulation by beta-adrenoceptors. Drug Chem Toxicol 2009, 32:175-181.
80. Al-Wadei H.A., Al-Wadei M.H., Schuller H.M. Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: a novel target for intervention. PLoS ONE 2012, 7:e29915.
81. Al-Wadei H.A., Plummer H.K., Schuller H.M. Nicotine stimulates pancreatic cancer xenografts by systemic increase in stress neurotransmitters and suppression of the inhibitory neurotransmitter gamma-aminobutyric acid. Carcinogenesis 2009, 30:506-511.
82. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010, 188:759-768.
83. Li Z.J., Wu W.K., Ng S.S., Yu L., Li H.T., Wong C.C., et al. A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery. J Control Release 2010, 148:292-302.
84. Goel S., Wong A.H., Jain R.K. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med 2012, 2:a006486.
85. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011, 10:417-427.
86. Huang Y., Goel S., Duda D.G., Fukumura D., Jain R.K. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013, 73:2943-2948.
87. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91:1071-1121.
88. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013, 31:2205-2218.
89. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
90. Moreno-Smith M., Lee S.J., Lu C., Nagaraja A.S., He G., Rupaimoole R., et al. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia 2013, 15:502-510.
91. Chakroborty D., Sarkar C., Yu H., Wang J., Liu Z., Dasgupta P.S., et al. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci USA 2011, 108:20730-20735.
92. Audet M., Bouvier M. Insights into signaling from the beta2-adrenergic receptor structure. Nat Chem Biol 2008, 4:397-403.
93. Evans B.A., Sato M., Sarwar M., Hutchinson D.S., Summers R.J. Ligand-directed signalling at beta-adrenoceptors. Br J Pharmacol 2010, 159:1022-1038.
94. Hara M.R., Kovacs J.J., Whalen E.J., Rajagopal S., Strachan R.T., Grant W., et al. A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1. Nature 2011, 477:349-353.
95. Luttrell L.M., Ferguson S.S., Daaka Y., Miller W.E., Maudsley S., Della Rocca G.J., et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999, 283:655-661.
96. de Rooij J., Zwartkruis F.J., Verheijen M.H., Cool R.H., Nijman S.M., Wittinghofer A., et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396:474-477.
97. Breckler M., Berthouze M., Laurent A.C., Crozatier B., Morel E., Lezoualc'h F. Rap-linked cAMP signaling Epac proteins: compartmentation, functioning and disease implications. Cell Signal 2011, 23:1257-1266.
98. Drake M.T., Violin J.D., Whalen E.J., Wisler J.W., Shenoy S.K. Lefkowitz RJ. beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem 2008, 283:5669-5676.
99. Armaiz-Pena G.N., Allen J.K., Cruz A., Stone R.L., Nick A.M., Lin Y.G., et al. Src activation by beta-adrenoreceptors is a key switch for tumour metastasis. Nat Commun 2013, 4:1403.
100. Shahzad M.M., Arevalo J.M., Armaiz-Pena G.N., Lu C., Stone R.L., Moreno-Smith M., et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 2010, 285:35462-35470.
101. Perron L., Bairati I., Harel F., Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004, 15:535-541.
102. Algazi M., Plu-Bureau G., Flahault A., Dondon M.G., Le M.G. Could treatments with beta-blockers be associated with a reduction in cancer risk?. Rev Epidemiol Sante Publique 2004, 52:53-65.
103. Rodriguez C., Jacobs E.J., Deka A., Patel A.V., Bain E.B., Thun M.J., et al. Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 2009, 20:671-679.
104. Bangalore S., Kumar S., Kjeldsen S.E., Makani H., Grossman E., Wetterslev J., et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011, 12:65-82.
105. Powe D.G., Voss M.J., Zanker K.S., Habashy H.O., Green A.R., Ellis I.O., et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010, 1:628-638.
106. Barron T.I., Connolly R.M., Sharp L., Bennett K., Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 2011, 29:2635-2644.
107. Melhem-Bertrandt A., Chavez-Macgregor M., Lei X., Brown E.N., Lee R.T., Meric-Bernstam F., et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011, 29:2645-2652.
108. De Giorgi V., Grazzini M., Gandini S., Benemei S., Lotti T., Marchionni N., et al. Treatment with beta-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011, 171:779-781.
109. Lemeshow S., Sorensen H.T., Phillips G., Yang E.V., Antonsen S., Riis A.H., et al. beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011, 20:2273-2279.
110. Shah S.M., Carey I.M., Owen C.G., Harris T., Dewilde S., Cook D.G. Does beta-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 2011, 72:157-161.
111. Powe D.G., Entschladen F. Targeted therapies: using beta-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 2011, 8:511-512.
112. Ganz P.A., Cole S.W. Expanding our therapeutic options: beta blockers for breast cancer. J Clin Oncol 2011, 29:2612-2616.
113. Al-Wadei H.A., Al-Wadei M.H., Ullah M.F., Schuller H.M. Celecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed mice. PLoS ONE 2012, 7:e43376.
114. Masur K., Niggemann B., Zanker K.S., Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001, 61:2866-2869.
115. Shin V.Y., Wu W.K., Chu K.M., Koo M.W., Wong H.P., Lam E.K., et al. Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells. Toxicol Sci 2007, 96:21-29.
116. Park P.G., Merryman J., Orloff M., Schuller H.M. Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res 1995, 55:3504-3508.
117. Ji Y., Chen S., Li K., Xiao X., Zheng S., Xu T. The role of beta-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells. Cell Div 2013, 8:1.